IR Biosciences (IRBS) Stock Price, News & Analysis

Company Overview

IR Biosciences Inc (OTCMKTS:IRBS) is a clinical-stage biotechnology company specializing in the development of precision oncology therapies. The firm’s research focuses on novel small-molecule agents designed to exploit specific DNA repair deficiencies in tumor cells. By targeting key vulnerabilities in cancer pathways, IR Biosciences aims to deliver more effective treatments with improved safety profiles compared with traditional chemotherapies.

The company’s lead candidate, IR-1, builds on a DNA-damaging mechanism that preferentially affects tumors with homologous recombination repair defects. IR Biosciences employs a proprietary biomarker-driven patient selection approach to identify individuals most likely to benefit from its therapies, optimizing clinical outcomes and streamlining development. In addition to its flagship program, the company’s pipeline includes preclinical assets targeting other DNA repair and cell cycle pathways.

Founded in the early 2020s and based in Delaware, IR Biosciences is led by a management team with extensive experience in oncology drug development and commercialization. The company currently conducts clinical trials at multiple leading oncology centers across North America, with plans to expand its clinical footprint into Europe and Asia to support global registration efforts.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IRBS Stock Analysis - Frequently Asked Questions

How do I buy shares of IR Biosciences?

Shares of IRBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IRBS
• CIK: N/A
• Web: www.immuneregen.com
• Phone: (480) 922-3926
• Fax: 480-922-4781
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A